Find Academic Supervisors

Peter BühlmannView profile

Professor

• High-dimensional Statistics
• Causal Inference
• Machine Learning
• +3 more

Peter Bühlmann is a Professor at ETH Zürich within the Seminar für Statistik , focusing on high-dimensional statistics, causal inference, and machine learning. His work bridges theoretical advancements with practical software implementations in R packages like pcalg , mboost , and glmmlasso , impacting fields such as genomics, proteomics, and intensive care analytics. Key Contributions : Causal structure learning, stability selection, anchor regression, and deconfounding. Software : Developed widely used R packages for statistical modeling and causal inference. Teaching : Courses on high-dimensional statistics at ETH Zürich and international institutions. Research Trends : Recent articles emphasize causal robustness, domain adaptation, and applications in medicine. His work addresses challenges in heterogeneous data, missing values, and covariate shifts using methods like spectral deconfounding and residual prediction tests. Scientific Recognition : Co-author of a paper designated as a New Hot Paper (Meinshausen and Bühlmann, 2006) by Essential Science Indicators, indicating significant impact in high-dimensional multiple testing.

• Environmental Health Engineering
• Wastewater-Based Epidemiology
• Bioremediation
• +7 more

Rolf Halden is a Professor and Center Director at Arizona State University, holding appointments in the School of Sustainable Engineering and the Built Environment, the Biodesign Center for Environmental Health Engineering, and the Global Futures Scientists and Scholars program. He is a leading expert in environmental health engineering, wastewater-based epidemiology, and bioremediation. Education: Ph.D. in Civil (Environmental) Engineering, University of Minnesota (1997) M.S. in Civil (Environmental) Engineering, University of Minnesota (1994) M.S. in Biology, Technical University of Braunschweig, Germany (1992) Postdoctoral Fellow, Environmental Science, Lawrence Livermore National Laboratory (1998) Research Focus: Halden’s research integrates environmental chemistry, public health, and sustainability to understand how anthropogenic chemicals affect ecological and human health. His lab uses advanced mass spectrometry (LC-MS/MS, MALDI-TOF) to track pollutants such as PPCPs, microplastics, pesticides, and dioxins across air, water, soil, and biological systems. He pioneered the use of wastewater treatment plants as public health observatories, enabling real-time tracking of disease, drug use, and environmental exposures. Scientific Awards & Recognition: Leadership Award, Arizona State University (2018) Rocky Mountain Emmy Award (2018) Leroy E. Burney Lecturer, Johns Hopkins School of Public Health (2011) ACS Expert Program Member (2014–present) NIEHS Superfund R01 Working Group National Leader (2012–2014) Labs & Teams: Halden is the Founding Director of the Biodesign Center for Environmental Health Engineering at ASU, where he leads a multidisciplinary team focused on environmental proteomics, bioremediation, and diagnostic tool development. He also co-leads the Human Health Observatory , a national wastewater monitoring network. Grants & Funding: Halden has secured major funding from NSF, NIH, EPA, DoD, and private industry. Notable projects include the development of in-situ groundwater monitoring devices, national wastewater surveillance of SARS-CoV-2, and studies on microplastics and neurodegenerative disease.

Daniel FinleyView profile

Professor

• Ubiquitin-Proteasome Pathway
• Proteostasis
• Protein Degradation
• +7 more

Daniel Finley is a Professor of Cell Biology at Harvard Medical School (HMS), leading the Finley Lab focused on the ubiquitin-proteasome pathway and related regulatory mechanisms. He holds academic appointments within the Department of Cell Biology and sits on the Scientific Advisory Boards of Proteostasis and X-Chem Pharmaceuticals. His research investigates proteasome function, ubiquitin-like proteins, and proteostasis roles in diseases like Alzheimer’s and ALS. Dr. Finley earned his undergraduate degree in biochemistry from Harvard University and a Ph.D. in molecular biology from MIT. After postdoctoral training at MIT, he joined HMS in 1988. His lab explores topics including erythroid proteome remodeling, mitochondrial dysfunction, and neurodegenerative disease mechanisms. Key research areas include: (1) Ubiquitin-proteasome pathway regulation, (2) Proteasome structure/function, (3) Nonproteolytic roles of ubiquitination, and (4) Pathophysiological roles of proteostasis defects in diseases. His work bridges basic cell biology with translational medicine, particularly in neurodegeneration and anemia. Finley has secured NIH funding for projects like 'Regulation of Proteasome Activity' (R35GM145246) and 'Erythrocyte maturation through global proteome remodeling' (R01HL153970). Collaborations with industry and academic partners extend his impact in drug discovery and proteasome-targeted therapies. His lab’s contributions include defining ubiquitin chain editing mechanisms, identifying USP14’s role in mitophagy, and elucidating proteostasis defects in Alzheimer's models. Research tools developed include advanced cryo-EM analyses of proteasomal structures and functional assays for ubiquitin system enzymes.

• Microbiology
• Immunology
• Bacterial Vaccines
• +5 more

James B. Kaper is a Professor and Chair of the Department of Microbiology & Immunology at the University of Maryland School of Medicine. He serves as Vice Dean for Academic Affairs and previously held leadership roles as Senior Associate Dean (2014–2019) and Chair (2007–present). His research focuses on the molecular pathogenesis of diarrheagenic Escherichia coli and Vibrio cholerae , including vaccine development and bacterial-host interactions. Education: BS (1973) and PhD (1979) in Microbiology from University of Maryland; Postdoc in Molecular Pathogenesis at University of Washington (1979–1981) Dr. Kaper’s work has led to the creation of live attenuated cholera vaccines, including CVD 103-HgR, the first licensed recombinant bacterial vaccine. His lab investigates bacterial genetics, intestinal colonization, and immune system activation, particularly TLR5 response to V. cholerae flagellin. He has authored 303 peer-reviewed articles and 68 book chapters. His research has been funded continuously by NIAID since 1982. Key publications include foundational work on V. cholerae vaccines (1984), genomic structure (1998), and quorum sensing in EHEC/EPEC (1999). His lab’s recent studies focus on phosphotyrosine proteomics (2013) and pathogenicity island regulation (2007). Scientific awards: Fellow, American Academy of Microbiology (1994); NIH Merit Award (2004); ASM DC White Award (2019) Editorial roles: Editor-in-Chief, EcoSal (2006–present); Associate Editor, International Journal of Medical Microbiology (2000–present) As an academic leader, Dr. Kaper has mentored over 60 graduate students and postdoctoral fellows. He holds multiple patents for cholera vaccines and E. coli diagnostics, including U.S. Patents 4,935,364; 5,399,494; and 6,204,004. His lab at UMSOM combines basic science with translational applications for enteric disease prevention.

Alexis BattleView profile

Associate Professor

• Genomics
• Machine Learning
• Computational Biology
• +3 more

Alexis Battle is an Associate Professor at Johns Hopkins University with appointments in Biomedical Engineering , Computer Science , and Genetic Medicine (secondary). She directs the Malone Center for Engineering in Healthcare and serves as Deputy Director of the Data Science and AI Institute . Educated at Stanford University (PhD in Computer Science, 2013), Battle transitioned to academia after leadership roles at Google. Research Focus: Battle’s work bridges genomics and machine learning , emphasizing the impact of genetic variation on human health. Her lab develops tools like Watershed to predict functional effects of rare variants, aiming to enhance rare disease diagnosis. Key themes include non-coding DNA analysis , personalized genomics , and systems biology , with applications in cardiovascular disease and neurodegenerative disorders . Publications & Awards: Over 60 peer-reviewed articles in journals like Nature , Science , and Genome Biology , with recent emphasis on single-cell transcriptomics , multiomics integration , and telomere biology . Recipient of the President’s Frontier Award (2022), Microsoft Investigator Fellowship (2019), and Searle Scholar (2016). Scientific Awards: 2022 President’s Frontier Award 2019 Microsoft Investigator Fellowship 2019 Johns Hopkins Discovery Award 2017 Johns Hopkins Catalyst Award 2016 Searle Scholar Advising & Funding: Mentors 11 PhD students, 3 undergraduates, and postdoctoral fellows. Her research is funded by NIH, Searle Scholars, and institutional grants. The Battle Lab collaborates on projects like the GTEx Consortium , focusing on gene regulation and clinical genomics .

• RNA Biology
• Bioinformatics
• Plant Molecular Biology
• +4 more

Peter Brodersen is a Professor at the Department of Biology, University of Copenhagen , specializing in Bioinformatics and RNA Biology . His research focuses on RNA modification (m6A), YTHDF proteins, and small RNA pathways in plants. Recent research trends from his group include: (1) molecular mechanisms of ARGONAUTE-small RNA interactions, (2) m6A-YTHDF regulatory systems in plant development, and (3) RNAi-independent roles of DICER-LIKE proteins in antiviral defense. Collaborations span Denmark and international institutions. Publications highlight cross-disciplinary work bridging computational biology and experimental plant genetics. Key subfields include RNA structure, epigenetic regulation, and antiviral immunity.

Laura EloView profile

Professor

• Computational Biomedicine
• Medical Bioinformatics
• Data Science
• +7 more

Laura Elo serves as Professor of Computational Medicine and Head of the Medical Bioinformatics Centre at the University of Turku, Finland. She concurrently holds the position of Research Director at Turku Bioscience Centre and acts as InFLAMES Flagship Contact, driving interdisciplinary biomedical research initiatives. Her academic foundation includes a PhD in Applied Mathematics (2007) and Adjunct Professorship in Biomathematics (2011), establishing her quantitative expertise before transitioning into biomedical applications. Her research program focuses on transforming molecular and clinical datasets through statistical modeling and advanced machine learning . Key thrusts include robust computational tools for proteome/epigenome analysis, AI-driven digital health diagnostics, and computational systems immunology for immune-mediated diseases. This work directly addresses challenges in reproducibility and scalability of high-throughput biotechnology data. Analysis of her recent publications reveals dominant themes in type 1 diabetes biomarker discovery , multi-omics integration , and immune system modeling , with strong emphasis on clinical translation through collaborations with experimental and medical teams. Her scientific recognition includes: JDRF Career Development Award Professor Elo actively trains MSc/PhD students and postdoctoral fellows while leading major research initiatives including ERC grants. Her teaching portfolio spans Bioinformatics Journal Club, AI in Diagnostics, and Systems Biology courses. The Elo Lab (https://elolab.utu.fi) operates as a hub for computational biomedicine, developing open-source tools like CellRomeR while maintaining close ties with Turku Bioscience Centre's experimental facilities for validating computational predictions in immunology and metabolic disease contexts.

Thibault MayorView profile

Professor

• Protein Homeostasis
• Ubiquitin Proteasome System
• Neurodegenerative Diseases
• +7 more

Thibault Mayor is a Professor in the Department of Biochemistry and Molecular Biology and the Michael Smith Laboratories at the University of British Columbia (Vancouver). His research focuses on understanding how cells manage misfolded proteins, with implications for neurodegenerative diseases like Parkinson's and Alzheimer's. He holds academic affiliations with the Centre for High-Throughput Biology (CHiBi) and has been recognized with awards including the UBC Killam Teaching Award (2020). Education: BSc, University of Geneva, Switzerland (1997) PhD, University of Geneva & Max Planck Institute of Biochemistry, Germany (2001) Postdoctoral Fellow, California Institute of Technology (2002) Research Interests: Mayor's lab investigates protein homeostasis, ubiquitin-proteasome system dynamics, and the molecular mechanisms underlying protein aggregation in aging and disease. Projects include proteomic approaches to identify aggregation-prone proteins and develop microbial cell factories for protein production. Grants & Awards: CIHR Project Grant ($730K, 2018) Michael Smith Foundation Career Award (2012) UBC Killam Teaching Award (2020) Labs & Collaborations: The Mayor Lab is part of the Michael Smith Laboratories and collaborates with computational biologists like Jörg Gsponer. They maintain active partnerships in proteomics and systems biology, contributing to initiatives like the BC Proteomics Network.

Knut ReinertView profile

Professor

• Algorithmic Bioinformatics
• Genomic Sequence Analysis
• Proteomics
• +7 more

Professor Knut Reinert is a leading figure in algorithmic bioinformatics at the Free University of Berlin, where he holds a professorship in the Department of Mathematics and Computer Science. He also maintains a significant affiliation with the Max Planck Institute for Molecular Genetics in Berlin, where he leads the Efficient Algorithms for Omics Data group. His research spans both institutions through the Reinert Lab, which focuses on developing novel computational approaches for biological data analysis. Reinert's educational background includes a Diploma in Computer Science (1994) and a Doctorate (Dr. Ing./Ph.D., 1999, with honors) from the Max-Planck-Institut for Computer Science and Universität des Saarlandes in Saarbrücken. Prior to his professorship, he worked as a computer scientist under Prof. Gene Myers at Celera Genomics in Rockville, USA (1999-2002). His primary research interests center on algorithmic bioinformatics with specific focus on developing novel algorithms and data structures for biomedical mass data analysis. This includes creating mathematical models for genomic sequence analysis and algorithms for mass spectrometry data to detect differential protein expression between normal and diseased samples. His work bridges the gap between computational tool development and practical biological applications, with particular emphasis on NGS and proteomics data. The publications and projects led by Prof. Reinert demonstrate a consistent focus on advancing computational methods in bioinformatics. His research spans genomic sequence analysis, RNA research (particularly long non-coding RNAs), parallel computing applications, and GPU acceleration for biological data processing. The work shows increasing sophistication in handling large-scale biological datasets through innovative algorithmic approaches. Intel® Parallel Computing Center designation for his lab CUDA Research Center status DFG funding of 530 thousand Euros for RNA research de.NBI funding of 2 million Euros BMBF funded projects 'LIVE-DREAM' and 'EssBar' Prof. Reinert leads multiple significant research projects and has established strong collaborations with international partners including Texas A&M, Kings College London, Eberhardt-Karls Universität Tübingen, Robert-Koch-Institute, and various Turkish institutions. His lab receives funding from major organizations including DFG, BMBF, and Intel. The Reinert Lab maintains active teaching responsibilities at FU Berlin, offering courses at BSc, MSc, and PhD levels using both traditional and innovative learning concepts like e-learning and inverted classrooms. The Reinert Lab consists of two interconnected research groups that work closely with experimental biologists and medical researchers to develop practical computational solutions for real-world biological problems. The lab has established itself as a key player in the German and international bioinformatics community through its development of the widely-used SeqAn library and participation in national infrastructure initiatives.

David R. KoesView profile

Associate Professor

• Computational Drug Discovery
• Machine Learning in Biology
• Open Source Software
• +3 more

David R. Koes is an Associate Professor in the Department of Computational and Systems Biology at the University of Pittsburgh, affiliated with the School of Medicine. He holds roles such as Associate Director of the Joint CMU-Pitt Computational Biology PhD Program (CPCB) and is involved in multiple graduate programs including Intelligent Systems and Computational Biomedicine. His research focuses on developing computational algorithms and systems for drug discovery, emphasizing open-source software and machine learning applications in biomedical data. Koes teaches courses like MSCBIO2025 (Bioinformatics Programming in Python) and MSCBIO2065 (Scalable Machine Learning for Big Data Biology). He has secured NIH funding (R35GM140753) and collaborated on projects with institutions like NVIDIA and Google Cloud. His lab develops tools such as GNINA, Pharmit, and 3Dmol.js, and actively contributes to open drug discovery initiatives. Education: PhD in Computer Science from Carnegie Mellon University (CMU). Research Interests: Leveraging computation and AI for drug design, molecular docking, pharmacophore modeling, and open science. Specific areas include developing scalable machine learning pipelines, virtual screening systems, and tools for 3D molecular analysis. Grants and Funding: Current NIH R35 grant and prior support from NSF, Relay Therapeutics, and others. His work emphasizes translating computational methods into practical drug discovery solutions. Lab and Teams: Directs a lab focused on computational drug discovery, collaborating with multiple academic and industry partners. Supervises graduate students and postdocs in projects spanning AI-driven drug design, molecular modeling, and software development.

Steven G. ClarkeView profile

Professor

• Biochemistry
• Systems Biology
• Biological Regulation
• +8 more

Dr. Steven G. Clarke is a Distinguished Professor at UCLA Department of Chemistry & Biochemistry and director of research at the Molecular Biology Institute . His work bridges protein chemistry , methylation biology , and aging research through studies of spontaneous protein damage and its repair mechanisms. Education: BA in Chemistry and Zoology, Pomona College (magna cum laude, Phi Beta Kappa) PhD in Biochemistry and Molecular Biology, Harvard University (NSF Fellow) Postdoctoral Fellowship at UC Berkeley (Miller Fellow) Dr. Clarke's research focuses on protein isoaspartyl repair via PCMT1/PIMT enzymes , ribosomal protein methylation in Saccharomyces cerevisiae , and PRMT family characterization including PRMT7 and PRMT9. His lab combines biochemical assays , genetic models , and structural analysis to investigate aging mechanisms and disease implications. Recent publications highlight: COQ5 structure-function analysis in coenzyme Q biosynthesis PCMTD1 ubiquitin ligase interactions PRMT7 substrate specificity in histone H2B Protein isoaspartyl impacts on T cell function in lupus Novel PRMT inhibitors for cancer therapy Methionine addiction in osteosarcoma malignancy Major scientific awards: American Chemical Society Ralph F. Hirschmann Award in Peptide Chemistry NIH MERIT Award Ellison Medical Foundation Senior Scholar Award William C. Rose Award, ASBMB UCLA Distinguished Teaching Award (Eby Award winner) Current lab members include PhD candidates Eric Pang (UCSB) and Sining "Cindy" Wang (UCLA), while undergraduates Celeste Medina-Seymoure , Elizabeth Oroudjeva , Olivia Pacheco , and Jasmine Winter contribute to ongoing proteostasis studies. Collaborations with Profs. Jose Rodriguez and Catherine Clarke demonstrate interdisciplinary research approaches.

Kelly ArnoldView profile

Associate Professor

• Biomedical Computation and Modeling
• Drug Delivery and Therapeutics
• Systems Immunology
• +5 more

Kelly Arnold is an Associate Professor in the Department of Biomedical Engineering at the University of Michigan. Her research integrates systems engineering principles with immunology to investigate variability in immune responses across infection, vaccination, and injury, with a focus on computational modeling and clinical translation. Research Focus Systems-level immune response modeling Vaccination and antibody functionality Vaginal microbiome-host interactions Chronic lung disease progression Computational serology and proteomics Recent Work Her 2025 studies examine SARS-CoV-2 vaccination responses in cancer patients and computational frameworks for vaginal probiotics. Earlier works (2024-2007) span COPD progression, lupus fibrosis, HIV susceptibility, and tissue engineering for fertility preservation. Methodologies include proteomic profiling, network modeling, and microfluidic systems.

David S. EisenbergView profile

Professor

• Protein Aggregation
• Amyloid Structures
• Prion Diseases
• +5 more

David S. Eisenberg is a Professor of Chemistry and Biochemistry and Biological Chemistry at the University of California, Los Angeles, where he also serves as Director of the UCLA-DOE Institute for Genomics and Proteomics and as an HHMI Investigator. His research focuses on protein interactions, particularly the structural basis for conversion of normal proteins to the amyloid state and conversion of prions to the infectious state. Dr. Eisenberg earned his undergraduate degree in biochemical sciences from Harvard College and his D.Phil. degree in theoretical chemistry from Oxford University on a Rhodes Scholarship. His postdoctoral research was on ice and water with Walter Kauzmann at Princeton and in protein crystallography with Richard Dickerson. He joined the UCLA faculty after his postdoctoral studies. Dr. Eisenberg and his research group focus on protein interactions in amyloid and prion diseases. These diseases involve protein aggregation where normal functional proteins convert to abnormal aggregated forms. Systemic amyloid diseases like dialysis-related amyloidosis result from fiber accumulation until organ failure, while neurodegenerative diseases like Alzheimer's, Parkinson's, ALS, and prion conditions appear to be caused by smaller oligomers. In 2005, his team determined the atomic-level structure for the amyloid fiber spine, revealing a 'steric zipper' of two parallel beta sheets packed across a dry interface. Since then, they've determined approximately 90 amyloid spines from 15 disease-related proteins. In 2010, they identified the structure of a toxic amyloid-related oligomer consisting of six anti-parallel beta strands forming a cylindrical barrel. His recent publications demonstrate continued innovation in amyloid research, with focus areas including structural prediction of amyloid formation, mechanisms of tau fibril disassembly in Alzheimer's disease, cryo-EM analysis of amyloid polymorphism, and structure-based design of inhibitors for amyloid toxicity. His work integrates computational, structural, and biochemical approaches to understand protein aggregation across multiple disease contexts. Dr. Eisenberg has received numerous prestigious awards and honors: National Academy of Sciences Member American Philosophical Society Member Institute of Medicine Member Howard Hughes Medical Institute Investigator Biophysical Society Emily M. Gray Award Harvard Westheimer Medal UCLA Seaborg Medal Technion - Israel Institute of Technology Harvey Prize in Human Health As Director of the UCLA-DOE Institute for Genomics and Proteomics and an HHMI Investigator, Dr. Eisenberg leads significant research initiatives in protein structure and aggregation. His laboratory combines X-ray crystallography, bioinformatics, and biochemical techniques to investigate protein interactions, with particular emphasis on amyloid-forming proteins and their role in disease. The Eisenberg Lab, located in Boyer Hall at UCLA, maintains an active research program investigating the structural basis of protein aggregation. The lab continues to build on its landmark discoveries of amyloid structures while exploring new frontiers in understanding protein misfolding diseases and developing potential therapeutic interventions.

Michele KlingbeilView profile

Professor

• Parasitology
• Molecular Biology
• Microbiology
• +4 more

Michele Klingbeil is a Professor in the Department of Microbiology at the University of Massachusetts Amherst, where she leads the Klingbeil DNA Replication Laboratory. She received her PhD in Cell and Molecular Biology from the University of Toledo in 1996 and previously worked at Johns Hopkins School of Medicine before moving to UMass in July 2007. Her educational background includes: PhD in Cell and Molecular Biology, University of Toledo, 1996 Dr. Klingbeil's research focuses on the unique biology of trypanosomatid parasites, particularly Trypanosoma brucei , the causative agent of African sleeping sickness. Her laboratory investigates two main areas: (1) replication of the unusual mitochondrial DNA network called kinetoplast DNA (kDNA), and (2) nuclear DNA replication initiation. Her work on kDNA is particularly significant as this structure is essential for parasite survival but has no counterpart in mammalian hosts, making it an attractive drug target. She employs a combination of reverse genetics (RNAi), cell biology, and biochemistry to understand the replication and repair mechanisms of kDNA, with a special focus on a family of four DNA polymerases related to bacterial Pol I. Dr. Klingbeil's recent publications reveal her laboratory's deep investigation into mitochondrial DNA polymerases in trypanosomatids, with discoveries showing multiple polymerases having specialized functions in kDNA replication and repair. Her research has established that several of these polymerases are essential for parasite viability, opening new avenues for drug development. She has also made significant contributions to understanding the simplified Origin Recognition Complex in trypanosomatids compared to other eukaryotes. Dr. Klingbeil has received the Thomas G. Lessie Distinguished Lectureship Award for her impact on teaching at the graduate level. Her research is funded by the National Institutes of Health, U.S. Department of Agriculture, the Joeph P. Healey Endowment, and the University of Massachusetts Amherst. She has mentored numerous graduate and undergraduate students, including current PhD candidates Dave Bruhn, Jeniffer Concepción, and Juemin Luo, as well as visiting scholar Eva Vidal Rico. Her former students have gone on to positions at institutions including Dana Farber/Broad Institute, Regis College, and Flagship Ventures. The laboratory regularly participates in scientific conferences including the Molecular Parasitology Meeting at Woods Hole and the Kinetoplastid Molecular Cell Biology conference. Dr. Klingbeil teaches several courses including Parasitology (MICRO 590S), Parasitology Lab (MICRO 590L), Molecular Mechanisms of Pathogenesis (MICRO 797P), Advanced Cell Biology (MCB 641), and Writing in Microbiology (MICRO 360). Her laboratory organizes regular social events including pumpkin carving parties and outings to Six Flags New England and Mt. Sugarloaf.

Daiwei ZhangView profile

Assistant Professor

• Artificial Intelligence
• Machine Learning
• Spatial Omics
• +3 more

Daiwei (David) Zhang, PhD, is an Assistant Professor (tenure-track) in the Department of Biostatistics at the University of North Carolina at Chapel Hill School of Medicine, with a joint appointment in the Department of Genetics. His research focuses on developing AI frameworks for analyzing high-dimensional biomedical data, particularly in spatial omics, computational pathology, and medical imaging. Education: MS (Biostatistics) and PhD (Biostatistics and Scientific Computing) from the University of Michigan. Postdoctoral Training: University of Pennsylvania. Research interests include applying machine learning to address biomedical challenges such as tumor heterogeneity, immune interactions, and tissue architecture. His work spans computational methods for spatial transcriptomics, proteomics, and histology integration. Recent publications emphasize spatial multi-omics analysis of cancer ecosystems, tertiary lymphoid structures, and metabolic coordination. These studies leverage advanced machine learning algorithms and interdisciplinary approaches to advance precision medicine. No scientific awards are explicitly mentioned, but his work reflects significant contributions to biomedical AI research. Grants and advising details are not provided in the text.